Evidence map›Paper›PMID 18633599›Full record

Trial reportKnee surgery, sports traumatology, arthroscopy : official journal of the ESSKA2008

Sclerosing injections to treat midportion Achilles tendinosis: a randomised controlled study evaluating two different concentrations of Polidocanol.

Lotta Willberg, Kerstin Sunding, Lars Ohberg, Magnus Forssblad, Martin Fahlström, Håkan Alfredson

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Injection therapies for Achilles tendinopathy.The Cochrane database of systematic reviews · 2015
    Pooled it
  2. No beneficial effect of Polidocanol treatment in Achilles tendinopathy: a randomised controlled trial.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2018
    Trial
  3. Review
  4. Review
  5. Review
  6. Chinese Consensus on Insertional Achilles Tendinopathy.Orthopaedic journal of sports medicine · 2019
    Article
  7. Article
  8. Article
  9. Review
  10. Non-insertional Achilles tendinopathy.EFORT open reviews · 2016
    Review
  11. Review
  12. Article
  13. Injection treatment for chronic midportion Achilles tendinopathy: do we need that many alternatives?Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2011
    Article
  14. Deciphering the pathogenesis of tendinopathy: a three-stages process.Sports medicine, arthroscopy, rehabilitation, therapy & technology : SMARTT · 2010
    Article
  15. Review
  16. New options in the management of tendinopathy.Open access journal of sports medicine · 2010
    Review
  17. Article
  18. Imaging of tendons.Sports health · 2009
    Article
  19. Does the dosage matter in sclerosing polidocanol injections in Achilles tendinopathy?Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2009
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Lotta WillbergCapio Artro Clinic, Stockholm Sports Trauma Research Centre, Karolinska Institute, 114 86, Stockholm, Sweden.
Kerstin Sunding
Lars Ohberg
Magnus Forssblad
Martin Fahlström
Håkan Alfredson
Karolinska Institutet · SEUmeå University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two to three ultrasound (US) and colour Doppler (CD)-guided injections of the sclerosing substance Polidocanol (5 mg/ml) have been demonstrated to give good clinical results in patients with chronic midportion Achilles tendinopathy. This study aimed to investigate if a higher concentration of Polidocanol (10 mg/ml) would lead to a less number of treatments, and lower volumes, needed for good clinical results. Fifty-two consecutive Achilles tendons (48 patients, mean age 49.6 years) with chronic painful midportion Achilles tendinopathy, were randomised to treatment with Polidocanol 5 mg/ml (group A) or 10 mg/ml (group B). The patients and treating physician were blinded to the concentration of Polidocanol injected. All patients had structural tendon changes and neovascularisation in the Achilles midportion. Treatment was US + CD-guided injections targeting the region with neovascularisation (outside ventral tendon). A maximum of three treatments (6-8 weeks in between) were given before evaluation. Patients not satisfied after three treatments were given additional treatment with Polidocanol 10 mg/ml, up to five treatments. For evaluation, the patients recorded the severity of Achilles tendon pain during activity on a visual analogue scale (VAS), before and after treatment. Patient satisfaction with treatment was also assessed. At follow-up (mean 14 months) after three treatments, 18/26 patients in group A and 19/26 patients in group B were satisfied with the treatment and had a significantly reduced level of tendon pain (P < 0.05). After completion of the study, additional treatments with Polidocanol 10 mg/ml in the not satisfied patients resulted in 26/26 satisfied patients in both groups A and B. In summary, we found no significant differences in the number of satisfied patients, number of injections or volumes given, between patients treated with 5 or 10 mg/ml Polidocanol.

Indexed as

Achilles TendonAdultAgedDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleHumansMaleMiddle AgedPain MeasurementPatient SatisfactionPolidocanolPolyethylene GlycolsRadiographySclerosing SolutionsPolidocanolPolyethylene GlycolsSclerosing Solutions

Identifiers

PMID18633599
OpenAlexW2028003208

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.